MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer


MADRID, Oct. 21, 2023 /PRNewswire/ — MEDSIR, a company specializing in the strategic design of independent clinical research, today presented the results of three new studies at the European Society for Medical Oncology (ESMO 2023), one of the most prestigious oncology platforms for…

Leave a Reply